Patents Assigned to Genentech, Inc.
  • Anti-FcRH5 antibodies
    Patent number: 10435471
    Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: October 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
  • Tricyclic PI3K inhibitor compounds and methods of use
    Patent number: 10435414
    Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: October 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190300544
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 3, 2019
    Applicant: GENENTECH, INC.
    Inventors: Steven MCKERRALL, Brian Salvatore SAFINA, Aleksandr KOLESNIKOV, Birong ZHANG, Wenfeng LIU, Kwong Wah LAI
  • CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20190300559
    Abstract: The invention relates generally to a calicheamicin molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody directly conjugated by a disulfide to one or more calicheamicin molecules.
    Type: Application
    Filed: June 18, 2019
    Publication date: October 3, 2019
    Applicant: Genentech, Inc.
    Inventor: Thomas Pillow
  • Cystine knot scaffold platform
    Patent number: 10428125
    Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: October 1, 2019
    Assignee: Genentech, Inc.
    Inventors: Rami Hannoush, Harini Kaluarachchi, Aaron Nile, Cameron Noland, Yingnan Zhang, Lijuan Zhou, Xinxin Gao
  • PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROP AN AMIDE
    Publication number: 20190292201
    Abstract: Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound 18, having the structure:
    Type: Application
    Filed: June 14, 2019
    Publication date: September 26, 2019
    Applicant: Genentech, Inc.
    Inventors: Francis GOSSELIN, Chong HAN, Theresa CRAVILLION, Sean M. KELLY, Scott SAVAGE
  • Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele
    Patent number: 10421984
    Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: September 24, 2019
    Assignee: Genentech, Inc.
    Inventors: Michael W. Laird, Karthik Veeravalli
  • Anti-HtrA1 antibodies and methods of use thereof
    Patent number: 10421821
    Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: September 24, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Daniel K. Kirchhofer, Joyce Lai, Chingwei V. Lee, Wei-Ching Liang, Michael T. Lipari, Kelly M. Loyet, Tao Sai, Menno Van Lookeren Campagne, Yan Wu, Germaine Fuh
  • OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20190284189
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 19, 2019
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Daniel SHORE, Elisia VILLEMURE, Matthew VOLGRAF, Baihua HU, Aijun LU, Andrew CRIDLAND, Stuart WARD, Francis BEAUMIER, Martin DERY, Robin LAROUCHE-GAUTHIER
  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20190284179
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: March 15, 2019
    Publication date: September 19, 2019
    Applicant: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • Anti-CD79B Antibodies and Immunoconjugates and Methods of Use
    Publication number: 20190276550
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: August 22, 2013
    Publication date: September 12, 2019
    Applicant: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Anti-factor D antibodies and conjugates
    Patent number: 10407510
    Abstract: The invention provides anti-Factor D antibodies and conjugates and methods of using the same.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: September 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Whitney Shatz, Devin Tesar, Justin M. Scheer, Michelle Dion
  • Naphthyridines as inhibitors of HPK1
    Patent number: 10407424
    Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Bryan Chan, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Blake Daniels, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca
  • USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS
    Publication number: 20190270803
    Abstract: Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 5, 2019
    Applicant: Genentech, Inc.
    Inventors: ChinYu Lin, Theodore A. Omachi, Ryan P. Owen, Karl Yen, Yanan Zheng, Kendra Debusk
  • PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE
    Publication number: 20190270695
    Abstract: Processes are described for the preparation of F-benzoxazinorifamycin I: and intermediates for conjugation with an antibody.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: Genentech, Inc.
    Inventors: Stephan Bachmann, Serena Maria Fantasia, Michael Jansen, Stefan Koenig, Xin Linghu, Sebastian Rieth, Nathaniel L. Segraves, Andreas Zogg
  • METHOD FOR TREATING JOINT DAMAGE
    Publication number: 20190270824
    Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
    Type: Application
    Filed: April 15, 2019
    Publication date: September 5, 2019
    Applicant: Genentech, Inc.
    Inventors: Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman
  • Tetrahydronaphthalene estrogen receptor modulators and uses thereof
    Patent number: 10399939
    Abstract: Described herein are tetrahydronaphthalene compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: September 3, 2019
    Assignee: Genentech, Inc.
    Inventors: Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190263786
    Abstract: The invention provides a compound as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 29, 2019
    Applicant: GENENTECH, INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Kwong Wah LAI, Zhiguo LIU, Wenfeng LIU, Ramsay BEVERIDGE, Jean-Philippe LECLERC, Alexandre LEMIRE, Liang ZHAO, Claudio STURINO
  • ASSISTED MANUAL INJECTOR DEVICES AND METHODS
    Publication number: 20190262542
    Abstract: Various embodiments disclosed herein relate to needle-based injectors that incorporate a power assembly comprising a stored energy source and a rate control assembly. The power assembly may be further configured to allow the injection to be performed with more force than a user may be capable of delivering, while also allowing the user to maintain control of the injection process after the stored energy source has been released and the injection has begun, such the user may increase or decrease the rate of injection, or stop the injection, during the injection process. In various embodiments, the power assembly may comprise spring- or gas-based stored energy sources, and/or may comprise friction- or tension-based rate control assemblies. Described herein are also methods for injecting an agent using embodiments of the devices described here.
    Type: Application
    Filed: February 28, 2019
    Publication date: August 29, 2019
    Applicant: Genentech, Inc.
    Inventors: Gordon D. ROW, Andrew I. POUTIATINE, Neal SCHLATTER, Adrian BISCHOFF
  • PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA
    Publication number: 20190263921
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Application
    Filed: May 15, 2019
    Publication date: August 29, 2019
    Applicant: Genentech, Inc.
    Inventors: Martin GAWLITZEK, Shun LUO, Christina Teresa BEVILACQUA